tetano
Editor, Senior Moderator
Front Immunol
. 2024 Aug 30:15:1430928.
doi: 10.3389/fimmu.2024.1430928. eCollection 2024. Intranasal HD-Ad-FS vaccine induces systemic and airway mucosal immunities against SARS-CoV-2 and systemic immunity against SARS-CoV-2 variants in mice and hamsters
Peter Zhou[SUP] #[/SUP][SUP] 1 [/SUP], Jacqueline Watt[SUP] #[/SUP][SUP] 1 [/SUP], Juntao Mai[SUP] 1 [/SUP], Huibi Cao[SUP] 2 [/SUP], Zhijie Li[SUP] 1 [/SUP], Ziyan Chen[SUP] 2 3 [/SUP], Rongqi Duan[SUP] 2 [/SUP], Ying Quan[SUP] 1 [/SUP], Anne-Claude Gingras[SUP] 1 4 [/SUP], James M Rini[SUP] 1 5 [/SUP], Jim Hu[SUP] 2 3 [/SUP], Jun Liu[SUP] 1 [/SUP]
Affiliations
The outbreak of coronavirus disease 19 (COVID-19) has highlighted the demand for vaccines that are safe and effective in inducing systemic and airway mucosal immunity against the aerosol transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this study, we developed a novel helper-dependent adenoviral vector-based COVID-19 mucosal vaccine encoding a full-length SARS-CoV-2 spike protein (HD-Ad-FS). Through intranasal immunization (single-dose and prime-boost regimens), we demonstrated that the HD-Ad-FS was immunogenic and elicited potent systemic and airway mucosal protection in BALB/c mice, transgenic ACE2 (hACE2) mice, and hamsters. We detected high titers of neutralizing antibodies (NAbs) in sera and bronchoalveolar lavages (BALs) in the vaccinated animals. High levels of spike-specific secretory IgA (sIgA) and IgG were induced in the airway of the vaccinated animals. The single-dose HD-Ad-FS elicited a strong immune response and protected animals from SARS-CoV-2 infection. In addition, the prime-boost vaccination induced cross-reactive serum NAbs against variants of concern (VOCs; Beta, Delta, and Omicron). After challenge, VOC infectious viral particles were at undetectable or minimal levels in the lower airway. Our findings highlight the potential of airway delivery of HD-Ad-FS as a safe and effective vaccine platform for generating mucosal protection against SARS-CoV-2 and its VOCs.
Keywords: COVID-19; HD-Ad; SARS-CoV-2; adenoviral vector; intranasal delivery; vaccine.
. 2024 Aug 30:15:1430928.
doi: 10.3389/fimmu.2024.1430928. eCollection 2024. Intranasal HD-Ad-FS vaccine induces systemic and airway mucosal immunities against SARS-CoV-2 and systemic immunity against SARS-CoV-2 variants in mice and hamsters
Peter Zhou[SUP] #[/SUP][SUP] 1 [/SUP], Jacqueline Watt[SUP] #[/SUP][SUP] 1 [/SUP], Juntao Mai[SUP] 1 [/SUP], Huibi Cao[SUP] 2 [/SUP], Zhijie Li[SUP] 1 [/SUP], Ziyan Chen[SUP] 2 3 [/SUP], Rongqi Duan[SUP] 2 [/SUP], Ying Quan[SUP] 1 [/SUP], Anne-Claude Gingras[SUP] 1 4 [/SUP], James M Rini[SUP] 1 5 [/SUP], Jim Hu[SUP] 2 3 [/SUP], Jun Liu[SUP] 1 [/SUP]
Affiliations
- PMID: 39281669
- PMCID: PMC11392758
- DOI: 10.3389/fimmu.2024.1430928
The outbreak of coronavirus disease 19 (COVID-19) has highlighted the demand for vaccines that are safe and effective in inducing systemic and airway mucosal immunity against the aerosol transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this study, we developed a novel helper-dependent adenoviral vector-based COVID-19 mucosal vaccine encoding a full-length SARS-CoV-2 spike protein (HD-Ad-FS). Through intranasal immunization (single-dose and prime-boost regimens), we demonstrated that the HD-Ad-FS was immunogenic and elicited potent systemic and airway mucosal protection in BALB/c mice, transgenic ACE2 (hACE2) mice, and hamsters. We detected high titers of neutralizing antibodies (NAbs) in sera and bronchoalveolar lavages (BALs) in the vaccinated animals. High levels of spike-specific secretory IgA (sIgA) and IgG were induced in the airway of the vaccinated animals. The single-dose HD-Ad-FS elicited a strong immune response and protected animals from SARS-CoV-2 infection. In addition, the prime-boost vaccination induced cross-reactive serum NAbs against variants of concern (VOCs; Beta, Delta, and Omicron). After challenge, VOC infectious viral particles were at undetectable or minimal levels in the lower airway. Our findings highlight the potential of airway delivery of HD-Ad-FS as a safe and effective vaccine platform for generating mucosal protection against SARS-CoV-2 and its VOCs.
Keywords: COVID-19; HD-Ad; SARS-CoV-2; adenoviral vector; intranasal delivery; vaccine.